Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 18 years old (up to 18.99 years).
- You have newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia.
- You have not had prior chemotherapy (except what's allowed by the main study called INITIALL).
- You have started chemotherapy on the INITIALL study no more than 3 days ago.
- Your liver and kidney function tests are within acceptable limits.
- You are not pregnant, breastfeeding, and if you could become pregnant, you agree to use effective birth control during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers key health information at the start of treatment for children and teens newly diagnosed with certain types of leukemia or lymphoma. The goal is to find the best way to begin therapy right away, without waiting for extra tests.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This trial tests a new therapy plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma. It aims to improve outcomes for those with higher-risk features.
This study tests a new treatment plan for children and teens newly diagnosed with T-cell acute lymphoblastic leukemia (T-ALL). It aims to see if the approach is safe and works well, and might offer a more tailored therapy for this specific type of leukemia.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.